Literature DB >> 12493543

Synthesis and evaluation of 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-[11C]ethyl-1,3-dihydro-2H-benzimidazol-2-one as a brain ORL1 receptor imaging agent for positron emission tomography.

Mikako Ogawa1, Kentaro Hatano, Yasuhiro Kawasumi, Kiichi Ishiwata, Kazunori Kawamura, Satoshi Ozaki, Kengo Ito.   

Abstract

1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-[(11)C]ethyl-1,3-dihydro-2H-benzimidazol-2-one ([(11)C]CPEB) was synthesized by [(11)C]N-ethylation and evaluated as a potential brain ORL1 receptor imaging agent by positron emission tomography. The uptake of [(11)C]CPEB in the mouse brain was 1.9% dose/g, 2 min post-injection, and gradually decreased with time. Receptor-specific binding was observed, however, the contribution of other receptors was observed and the non-specific binding of [(11)C]CPEB was too high for imaging receptors in vivo. Therefore, [(11)C]CPEB is not a suitable tracer for in vivo ORL1 receptor imaging. Copyright 2002 Elsevier Science Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12493543     DOI: 10.1016/s0969-8051(02)00352-9

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  4 in total

Review 1.  Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

Authors:  Nurulain T Zaveri
Journal:  J Med Chem       Date:  2016-03-14       Impact factor: 7.446

2.  Brain and whole-body imaging of nociceptin/orphanin FQ peptide receptor in humans using the PET ligand 11C-NOP-1A.

Authors:  Talakad G Lohith; Sami S Zoghbi; Cheryl L Morse; Maria F Araneta; Vanessa N Barth; Nancy A Goebl; Johannes T Tauscher; Victor W Pike; Robert B Innis; Masahiro Fujita
Journal:  J Nucl Med       Date:  2012-02-06       Impact factor: 10.057

3.  Brain and whole-body imaging in rhesus monkeys of 11C-NOP-1A, a promising PET radioligand for nociceptin/orphanin FQ peptide receptors.

Authors:  Yasuyuki Kimura; Masahiro Fujita; Jinsoo Hong; Talakad G Lohith; Robert L Gladding; Sami S Zoghbi; Johannes A Tauscher; Nancy Goebl; Karen S Rash; Zhaogen Chen; Concepcion Pedregal; Vanessa N Barth; Victor W Pike; Robert B Innis
Journal:  J Nucl Med       Date:  2011-08-30       Impact factor: 10.057

4.  The NOP (ORL1) receptor antagonist Compound B stimulates mesolimbic dopamine release and is rewarding in mice by a non-NOP-receptor-mediated mechanism.

Authors:  Miwako Koizumi; Kazuto Sakoori; Naoko Midorikawa; Niall P Murphy
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.